These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
328 related articles for article (PubMed ID: 2985652)
1. Bone and parathyroid inhibitory effects of S-2(3-aminopropylamino)ethylphosphorothioic acid. Studies in experimental animals and cultured bone cells. Attie MF; Fallon MD; Spar B; Wolf JS; Slatopolsky E; Goldfarb S J Clin Invest; 1985 Apr; 75(4):1191-7. PubMed ID: 2985652 [TBL] [Abstract][Full Text] [Related]
2. Inhibition of parathyroid hormone secretion and parathyroid hormone-independent diminution of tubular calcium reabsorption by WR-2721, a unique hypocalcemic agent. Hirschel-Scholz S; Caverzasio J; Bonjour JP J Clin Invest; 1985 Nov; 76(5):1851-6. PubMed ID: 2997292 [TBL] [Abstract][Full Text] [Related]
3. In vivo and in vitro effects of WR-2721 in experimental hypercalcemia in the rat. Weiss J; Walker ST; Fallon M; Goldfarb S J Pharmacol Exp Ther; 1986 Sep; 238(3):969-73. PubMed ID: 3018229 [TBL] [Abstract][Full Text] [Related]
4. Interference of WR-2721 with magnesium metabolism: mechanism of action. Hirschel-Scholz S; Paunier L; Bonjour JP Miner Electrolyte Metab; 1988; 14(2-3):114-20. PubMed ID: 2837628 [TBL] [Abstract][Full Text] [Related]
5. Protection from progressive renal failure and hyperparathyroid bone remodeling by WR-2721. Hirschel-Scholz S; Charhon S; Rizzoli R; Caverzasio J; Paunier L; Bonjour JP Kidney Int; 1988 May; 33(5):934-41. PubMed ID: 2839727 [TBL] [Abstract][Full Text] [Related]
6. Hypocalcemia and inhibition of parathyroid hormone secretion after administration of WR-2721 (a radioprotective and chemoprotective agent). Glover D; Riley L; Carmichael K; Spar B; Glick J; Kligerman MM; Agus ZS; Slatopolsky E; Attie M; Goldfarb S N Engl J Med; 1983 Nov; 309(19):1137-41. PubMed ID: 6312315 [TBL] [Abstract][Full Text] [Related]
7. Prevention of parathyroid hormone-dependent nephrocalcinosis by chronic administration of the organic phosphorothioate WR-2721. Hirschel-Scholz S; Caverzasio J; Bonjour JP Calcif Tissue Int; 1987 Feb; 40(2):103-8. PubMed ID: 3032378 [TBL] [Abstract][Full Text] [Related]
8. Normalization of hypercalcemia associated with a decrease in renal calcium reabsorption in Leydig cell tumor-bearing rats treated with WR-2721. Hirschel-Scholz S; Caverzasio J; Rizzoli R; Bonjour JP J Clin Invest; 1986 Jul; 78(1):319-22. PubMed ID: 3013941 [TBL] [Abstract][Full Text] [Related]
9. Dual effects of a new hypocalcemic agent, WR-2721, on cytoplasmic Ca2+ and parathyroid hormone release of dispersed parathyroid cells from patients with hyperparathyroidism. Larsson R; Nygren P; Wallfelt C; Akerström G; Rastad J; Ljunghall S; Gylfe E Biochem Pharmacol; 1986 Dec; 35(23):4237-41. PubMed ID: 3024645 [TBL] [Abstract][Full Text] [Related]
10. WR-2721 reduces bone loss after hindlimb tenotomy in rats. Shaker JL; Fallon MD; Goldfarb S; Farber J; Attie MF J Bone Miner Res; 1989 Dec; 4(6):885-90. PubMed ID: 2558504 [TBL] [Abstract][Full Text] [Related]
11. Effect of fasting and parathyroid hormone injection on plasma 45Ca concentrations in rats. Talmage RV Calcif Tissue Res; 1975; 17(2):103-12. PubMed ID: 1139365 [TBL] [Abstract][Full Text] [Related]
12. Effect of rate of calcium reduction and a hypocalcemic clamp on parathyroid hormone secretion: a study in dogs. Estepa JC; Aguilera-Tejero E; Almaden Y; Rodriguez M; Felsenfeld AJ Kidney Int; 1999 May; 55(5):1724-33. PubMed ID: 10231434 [TBL] [Abstract][Full Text] [Related]
14. On the role of cyclic AMP as a mediator of bone resorption: gamma-interferon completely inhibits cholera toxin- and forskolin-induced but only partially inhibits parathyroid hormone-stimulated 45Ca release from mouse calvarial bones. Lerner UH; Ransjö M; Ljunggren O; Klaushofer K; Hoffmann O; Peterlik M J Bone Miner Res; 1991 Jun; 6(6):551-60. PubMed ID: 1653515 [TBL] [Abstract][Full Text] [Related]
15. An interpretation of acute changes in plasma 45Ca following parathyroid hormone administration to thyroparathyroidectomized rats. Talmage RV; Doppelt SH; Fondren FB Calcif Tissue Res; 1976 Dec; 22(2):117-28. PubMed ID: 1000348 [TBL] [Abstract][Full Text] [Related]
16. Treatment of hypercalcemia in parathyroid cancer with WR-2721, S-2-(3-aminopropylamino)ethyl-phosphorothioic acid. Glover DJ; Shaw L; Glick JH; Slatopolsky E; Weiler C; Attie M; Goldfarb S Ann Intern Med; 1985 Jul; 103(1):55-7. PubMed ID: 2988391 [TBL] [Abstract][Full Text] [Related]
17. Effects of forskolin on bone resorption in the absence and presence of parathyroid hormone and calcitonin. Conaway HH; Abraham RL; Wadkins CL Calcif Tissue Int; 1987 May; 40(5):276-81. PubMed ID: 3107781 [TBL] [Abstract][Full Text] [Related]
18. Calcitonin and the bone fluid compartment: effect of calcitonin and/or parathyroid hormone on plasma radiocalcium changes. Dopplet SH; Talmage RV Clin Orthop Relat Res; 1976; (118):242-50. PubMed ID: 954281 [TBL] [Abstract][Full Text] [Related]
19. Role of bone and kidney in parathyroid hormone-related peptide-induced hypercalcemia in rats. Rizzoli R; Caverzasio J; Chapuy MC; Martin TJ; Bonjour JP J Bone Miner Res; 1989 Oct; 4(5):759-65. PubMed ID: 2554691 [TBL] [Abstract][Full Text] [Related]
20. Maintenance of normocalcemia by continuous infusion of the synthetic bovine parathyroid hormone (1-34) in parathyroidectomized rats. Ibrahim MM; Forte LR; Thomas ML Calcif Tissue Int; 1982; 34(6):553-7. PubMed ID: 6819076 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]